Login to Your Account



Adcoms Recommend Higher Standards for Calcitonin Drugs

By Mari Serebrov
Washington Editor

Wednesday, March 6, 2013
Drugmakers with calcitonin salmon products under development for postmenopause osteoporosis (PMO) may have to do a lot more work to get the drugs approved following a joint FDA advisory committee meeting Tuesday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription